Today: 20 March 2026
Subscribe
Browse Category

NYSE:PEN 13 January 2026 - 30 January 2026

Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific stock snaps a 4-day run — what to watch before Feb. 4 earnings

Boston Scientific shares fell 1.6% to $92.33 Thursday, ending a four-day rally on heavy volume after the company completed its acquisition of Nalu Medical. The stock underperformed sector peers as investors awaited fourth-quarter results due Feb. 4 and looked for updates on recent deal activity, including the $14.5 billion Penumbra purchase.
30 January 2026
······
Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead

Boston Scientific (BSX) stock drops after $14.5B Penumbra deal; FDA nod and earnings date ahead

Boston Scientific shares fell 4% Thursday after it announced a $14.5 billion cash-and-stock deal to buy Penumbra at $374 per share. Penumbra stock jumped 12% to $350.49. Boston Scientific warned of near-term EPS dilution and will fund about $11 billion in cash using debt and existing funds. Investors are watching for more details ahead of Boston Scientific’s earnings report on Feb. 4.
16 January 2026
···

Stock Market Today

  • Diageo Shares Fall 22% in One Month Amid Valuation Debate
    March 20, 2026, 10:31 AM EDT. Diageo PLC (LSE:DGE) has seen a sharp 22% drop in its share price over the past month, continuing a 16% decline across three months, reflecting investor reassessment of its growth and risk outlook. The stock currently trades at £14.02, about 29% undervalued against a £19.81 fair value estimate based on forecasts including 2.7% annual revenue growth and earnings rising to $4.3 billion by 2028. However, Diageo's price-to-earnings (P/E) ratio stands at 17.3, slightly above industry peers but below the fair ratio of 24.1, suggesting mixed market sentiment. Risks include changing alcohol consumption trends and emerging market volatility from regulatory and taxation pressures. Investors face a nuanced outlook balancing downside risks with potential upside from margin improvements and steady sales growth.
Go toTop